CorrespondenceLiver-related mortality in hepatitis delta patients: Russian single centre experience
Section snippets
Conflict of interest
There is no commercial relationship that might pose a conflict of interest in connection with the submitted manuscript for all Authors, except Dzhamal Abdurakhmanov who is Speaker and had grants for lectures and clinical trials from Merck, Gilead, Abbvie, BMS and R-Pharm.
References (8)
- et al.
A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma
Gastroenterology
(2009) - et al.
Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study
J Hepatol
(2013) - et al.
Outcome of chronic delta hepatitis in Italy: a long-term cohort study
J Hepatol
(2010) - et al.
Safety and efficacy of REP 2139 and pegylated interferon alfa- 2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial
Lancet Gastroenterol Hepatol
(2017)
There are more references available in the full text version of this article.
Cited by (2)
The changing context of hepatitis D
2021, Journal of HepatologyCitation Excerpt :In Europe, HDV remains endemic in Romania17 and Moldova.18 Hot spots sustained by immigrants and intravenous drug users (IVDUs) have been reported in Russia.19,20 IVDUs are the group at highest risk of hepatitis D.21 However, the HDV scenario is also changing in IVDUs in Europe, reflecting the impact of HBV vaccination and the success of harm reduction programmes.
Silent HDV epidemics culminates in high levels of liver cirrhosis in endemic region despite 20 years of HBV vaccination
2023, Journal of Viral Hepatitis
© 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.